Bevacizumab (Avastin) prior authorization at Premera Blue Cross
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Premera Blue Cross requires prior-authorization documentation for Bevacizumab (Avastin): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Premera Blue Cross reviews Bevacizumab (Avastin) prior authorizations against its medical policy . Premera Blue Cross-specific context: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Premera Blue Cross's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- WA-specific mental health parity violations
- Step therapy via Express Scripts
- Out-of-network reductions
- Specialty drug prior auth
Bevacizumab (Avastin)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Off-label use (ovarian, cervical maintenance)
- Plan-mandated biosimilar switch
- Site-of-care reduction
- Compounded intravitreal use denial (Avastin off-label for AMD)
Brand: Avastin. VEGF inhibitor. Biosimilars: Mvasi, Zirabev, Alymsys, Vegzelma, Avzivi. Off-label intravitreal use for wet AMD is widespread but commonly denied — appeals lean on AAO clinical practice and CATT trial.
Manufacturer patient-assistance program: Genentech Patient Foundation — relevant when a Premera Blue Cross denial sticks and the patient needs bridge access while appealing.
How Premera Blue Cross approaches Biosimilars PAs
For Bevacizumab, check whether the current Premera Blue Cross Biosimilars policy cites step therapy via express scripts or specialty drug prior auth. Pharmacy-benefit review for Bevacizumab at Premera Blue Cross is routed through Express Scripts. The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Premera Blue Cross; if denied, use the filing date and route printed on that denial notice. Premera Blue Cross treats interchangeability designation and prescriber "dispense-as-written" language as the two pivot points for biosimilar-vs-reference disputes. Premera Blue Cross is domiciled in WA, so unresolved appeals escalate to the WA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.premera.com/wa/provider) with the same packet plus an applicable, current clinical source supporting Bevacizumab (Avastin)for the patient's indication.
Contact Premera Blue Cross
- Provider portal: https://www.premera.com/wa/provider
Frequently asked questions
What documentation does Premera Blue Cross need for Bevacizumab (Avastin) prior auth?
Premera Blue Cross's typical PA packet for Bevacizumab (Avastin): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Premera Blue Cross?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for Bevacizumab (Avastin) at Premera Blue Cross?
Preparation scenarios to check against the current notice and policy include: WA-specific mental health parity violations; Step therapy via Express Scripts; Out-of-network reductions. These are not measured frequency claims. For Bevacizumab (Avastin), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Can Premera Blue Cross force a mid-treatment switch from the reference biologic to Bevacizumab?
Premera Blue Cross can require biosimilar use at initiation, but mid-treatment forced switches face higher appeal-reversal rates when the chart documents a stable patient, a defined transition-of-care concern, or prescriber "dispense-as-written" intent supported by a clinical rationale (immunogenicity history, nocebo response in prior switches, narrow therapeutic window). Cite the FDA Purple Book interchangeability designation when arguing the switch — interchangeable biosimilars permit pharmacy substitution; non-interchangeable biosimilars do not. Pharmacy-benefit handling is routed through Express Scripts. External-review escalation for Premera Blue Cross fully-insured policies sits with the WA insurance department.
How do I prep for a peer-to-peer with Premera Blue Cross on Bevacizumab (Avastin)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Bevacizumab (Avastin) PA packet
Open ApprovalHelp — generate a Bevacizumab (Avastin) prior-auth packet tailored to Premera Blue Cross's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com